3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Small Cell Lung Carcinoma
5
Melanoma
5
Neoplasm Metastasis
4
Neoplasms
3
Brain Neoplasms
3
Thymus Neoplasms
2
Pancreatic Neoplasms
2
Locally Advanced Non-small Cell Lung Cancer
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Interventions
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Fluorodeoxyglucose F18
2
Everolimus
2
Carboplatin
2
tislelizumab
1
taxane
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
olaparib
1
liposomal doxorubicin
1
entrectinib
1
cabozantinib
1
atezolizumab
1
alectinib
1
aldesleukin
1
Vinorelbine
1
Temozolomide
1
Specimen Handling
1
RRx-001
1
Quality of Life
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Immunotherapy
×
Thoracic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled